Key result
Adjunct pathogenetic therapies, including serine proteinase inhibitors, antioxidants, and chloroquine, may help prevent cell contamination and reduce replicative activity of respiratory RNA viruses.
The biological mechanisms of respiratory RNA viruses suggest that adjunct therapies targeting viral entry and oxidative stress, such as quercetin and ambroxol, could be beneficial.
Answers are grounded in this paper and cite their sources.
Should not yet change clinical practice for respiratory viruses; leaves open hypothesis-testing in prospective trials.
The characteristics of the biology of influenza viruses and coronavirus that determine the implementation of the infectious process are presented. With provision for pathogenesis of infection possible effects of serine proteinase inhibitors, heparin, and inhibitors of heparan sulfate receptors in the prevention of cell contamination by viruses are examined. It has been determined that chelators of metals of variable valency and antioxidants should be used for the reduction of replicative activity of viruses and anti-inflammatory therapy. The possibility of a pH-dependent impairment of glycosylation of cellular and viral proteins was traced for chloroquine and its derivatives. The use of low-toxicity drugs as part of adjunct therapy increases the effectiveness of synthetic antiviral drugs and interferons and ensures the safety of baseline therapy.
No takes yet. Share an insight, caveat, or question.
Чепур et al. (2021) conducted a review in Respiratory RNA viral infections (Influenza, Coronaviruses). Pathogenetic adjunct therapies (e.g., chloroquine, ambroxol, quercetin, heparin) was evaluated. Adjunct pathogenetic therapies, including serine proteinase inhibitors, antioxidants, and chloroquine, may help prevent cell contamination and reduce replicative activity of respiratory RNA viruses.
Synapse has enriched 10 related papers. Consider them for comparative context: